SIREN : 825034259
NORGINE PHARMA is a French company founded 9 years ago, specialized in the sector Fabrication de produits pharmaceutiques de base. Based in DREUX (28100), this company of category ETI shows in 2024 a revenue of 25.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 25 124 094 € | 23 655 369 € | 23 360 777 € | 24 093 188 € | 24 299 736 € | 21 255 508 € | 22 519 348 € | 16 603 524 € |
| Net income | 2 452 244 € | 450 114 € | -5 148 407 € | 212 047 € | -2 594 061 € | -4 003 095 € | 458 310 € | -216 060 € |
| EBITDA | 3 945 631 € | 45 959 € | 2 163 789 € | 1 006 600 € | 1 171 073 € | -428 357 € | 2 371 794 € | 1 326 518 € |
| Net margin | 9.8% | 1.9% | -22.0% | 0.9% | -10.7% | -18.8% | 2.0% | -1.3% |
In 2024, NORGINE PHARMA achieves revenue of 25.1 M€. Over the period 2017-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +6.1%. Vs 2023: +6%. After deducting consumption (4.8 M€), gross margin stands at 20.3 M€, i.e. a rate of 81%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 3.9 M€, representing 15.7% of revenue. Positive scissor effect: EBITDA margin improves by +15.5 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.5 M€, i.e. 9.8% of revenue. This profit can be retained or distributed to shareholders.
25 124 094 €
20 316 454 €
3 945 631 €
3 398 740 €
2 452 244 €
15.7%
The debt ratio (= Financial debt / Equity x 100) stands at 173%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 17%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.5 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 14.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
173.222%
17.242%
14.07%
1.549
28.5%
In 2024, the debt ratio of NORGINE PHARMA (173.22) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of NORGINE PHARMA (17.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of NORGINE PHARMA (1.55) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 79.67. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 16.7x. Operating income very largely covers interest expenses: high safety margin.
79.674
16.686
In 2024, the liquidity ratio of NORGINE PHARMA (79.67) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of NORGINE PHARMA (16.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 27 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 180 days. Excellent situation: suppliers finance 153 days of the operating cycle (retail model). Inventory turnover is 101 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 50 days of revenue, i.e. 3.5 M€ to permanently finance. Notable WCR improvement over the period (-52%), freeing up cash.
3 484 963 €
27 j
180 j
101 j
50 j
Compare NORGINE PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de produits pharmaceutiques de base
The revenue of NORGINE PHARMA in 2024 is 25.1 M€.
Yes, NORGINE PHARMA generated a net profit of 2.5 M€ in 2024.
The headquarters of NORGINE PHARMA is located in DREUX (28100), in the department Eure-et-Loir.
The tax return of NORGINE PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
NORGINE PHARMA operates in the sector Fabrication de produits pharmaceutiques de base (NAF code 21.10Z). See the 'Sector positioning' section above to compare the company with its competitors.